Moreover, when limiting those taking any cholinesterase inhibitors at less than half of the maximum approved doses in Japan (n = 12 for DLB, n = 15 for AD), the sensitivity was 83.3% (95% CI 51.6–97.9), the specificity 86.7% (59.5–98.3), and the accuracy 85.2% (66.3–95.8). The gene discussed is BCHE; the disease is Lewy body dementia.